Preclinical studies conducted with Sail’s Endless RNA demonstrate durable protein expression in vivo, enabling a prolonged therapeutic effect. This has a huge impact on how we think about biologic medicines, opening the door for RNA medicines to treat chronic diseases, especially those requiring intracellular or transmembrane protein replacement not amenable to biologics, with lower dose levels and less frequent administration.

A new therapeutic construct: Endless RNA

eRNA is a form of translatable circular RNA where the contiguous ring of single-stranded RNA lacks the cap and poly-A tail that cells normally use to control mRNA degradation.

Unlocking the full promise of RNA therapies

mRNA medicines have shown great promise, most notably in vaccines, but they have a relatively short duration of therapeutic protein expression, typically 1-2 days, which puts significant limitations on the types of disease that can be addressed and the performance of the medicines themselves. eRNA has the potential to overcome these challenges and unlock the full promise of RNA therapeutics.

Sail is expanding the design space for nanoparticles by orders of magnitude. By harnessing nature we have built an expanded chemical toolkit to program nanoparticles.  Sail’s nanoparticle platform has demonstrated the potential to exceed the in vivo performance of current lipid nanoparticle technologies.

A far greater toolkit

Sail has built an atlas of over 75,000 molecules (including natural components from across five kingdoms of life, as well as proprietary synthetic molecules).  Our atlas represents significantly more chemical diversity than what has been historically used in traditional lipid nanoparticles. By mining components from this vastly expanded toolkit, Sail can program nanoparticles for expanded functionality versus what is currently possible.

Driving superior performance for RNA-nanoparticle medicines

Sail programmable nanoparticles have already demonstrated unique cell and tissue tropism, amenability to new routes of administration, and frequent re-dosing in multiple animal models.

We’re using cutting-edge, proprietary AI techniques and rapid desugb-make-test iterations to accelerate our efforts to revolutionize RNA-based medicines.

Powered by unparalleled data generation

With our programmable eRNA technology and proprietary atlas of programmable nanoparticle components, Sail has dramatically expanded the RNA medicines design space. To interrogate this vast design space, we have built a high-throughput system that generates functional data at remarkable pace to create iterative learning loops leverage machine intelligence to predictably program RNA medicines.

Applying machine intelligence to comprehensively program RNA medicines to spec

With unmatched data flow and proprietary techniques, we’re able to apply AI to program in an integrated way across the pharmacology and delivery components of the medicine – i.e., RNA and nanoparticle – with the aim of driving breakthroughs in durability, efficiency, safety/tolerability and targeting – and ultimately delivering therapeutic benefits to patients that have previously been unreachable.